HOMA-IR vs HbA1c — two blood tests that both inform metabolic health, yet measure entirely different physiological processes. HOMA-IR estimates insulin resistance using fasting glucose and insulin levels, potentially identifying early metabolic dysfunction before blood sugar rises. HbA1c reflects average blood glucose over two to three months and is the NHS standard for diagnosing and monitoring type 2 diabetes. Understanding when each test is appropriate, what their results mean, and how they complement one another is essential for patients and clinicians navigating diabetes risk assessment and metabolic health.

What HOMA-IR and HbA1c Measure and Why They Differ

HOMA-IR estimates insulin resistance using fasting insulin and glucose, while HbA1c reflects average blood glucose over two to three months; they capture different stages of metabolic deterioration and are not interchangeable.

Have any more questions about this? Message our pharmaceutical team to get more info →

HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) and HbA1c (glycated haemoglobin) are both used to assess metabolic health, but they measure fundamentally different physiological processes. Understanding this distinction is essential for interpreting results accurately.

HOMA-IR is a calculated index derived from a fasting blood glucose level and a fasting insulin level, using the formula: fasting insulin (mU/L, equivalent to µU/mL) × fasting glucose (mmol/L) ÷ 22.5. It provides an indirect, model-based estimate of how resistant the body's cells are to the effects of insulin — a state that often precedes the development of type 2 diabetes by many years. A higher HOMA-IR score suggests greater insulin resistance. The original HOMA model was described by Matthews and colleagues in Diabetologia (1985); an updated version, HOMA2, is available via the Oxford Centre for Diabetes, Endocrinology and Metabolism and accounts for additional physiological variables.

HbA1c, by contrast, reflects the average blood glucose concentration over the preceding two to three months. Glucose binds to haemoglobin in red blood cells, and the proportion of glycated haemoglobin rises as average blood glucose increases. In the UK, HbA1c is expressed in mmol/mol (IFCC units), in line with NHS and WHO standardisation.

The key difference lies in what each test captures:

• HOMA-IR estimates early metabolic dysfunction — specifically, the compensatory hyperinsulinaemia that may occur before glucose levels rise significantly

• HbA1c detects sustained hyperglycaemia, which typically occurs at a later stage of metabolic deterioration

Because of this, the two tests are not interchangeable. They offer complementary windows into different stages of the same underlying disease process, which is why clinicians may use them together in certain clinical scenarios.

How Each Test Is Used in NHS Clinical Practice

HbA1c is the NHS primary tool for diagnosing and monitoring type 2 diabetes; HOMA-IR is not part of NICE diagnostic pathways and is used mainly in research and specialist metabolic clinics.

Within the NHS, HbA1c is the primary tool for both diagnosing type 2 diabetes and monitoring glycaemic control in people already living with the condition. UK practice is based on the WHO 2011 position statement on the use of HbA1c in the diagnosis of diabetes, as reflected in NICE Clinical Knowledge Summaries (CKS) and NHS guidance. A single HbA1c of 48 mmol/mol or above, confirmed on a second sample in asymptomatic individuals, is diagnostic of type 2 diabetes. A level of 42–47 mmol/mol indicates non-diabetic hyperglycaemia (NDH; sometimes referred to as prediabetes), which warrants lifestyle intervention and regular monitoring, as defined by Public Health England and NHS England.

HbA1c is widely available across NHS primary and secondary care settings, requires no fasting, and is standardised through the IFCC reference method. It is routinely used in:

• Annual diabetes reviews

• Monitoring response to medication such as metformin or SGLT2 inhibitors

• Informing diabetes management decisions (note: HbA1c is not a direct input to cardiovascular risk scoring tools such as QRISK, though good glycaemic control is an important component of overall cardiometabolic management)

HbA1c should not be used for diagnosis in the following groups, where fasting plasma glucose or an oral glucose tolerance test (OGTT) should be used instead:

• Children and young people

• Pregnant women (including for the diagnosis of gestational diabetes — see NICE NG3)

• Individuals with symptoms suggestive of type 1 diabetes or rapid-onset hyperglycaemia

• Those with acute illness

• People with haemoglobinopathies (e.g., sickle cell trait, thalassaemia), haemolytic anaemia, iron deficiency anaemia, or advanced chronic kidney disease (CKD)

• Those who have recently received a blood transfusion

HOMA-IR is not a standard NHS diagnostic test and is not part of NICE diagnostic pathways for routine clinical use. It requires both a fasting glucose and a fasting insulin measurement — the latter of which is not universally available in all NHS laboratories and is not routinely requested in primary care. As a result, HOMA-IR is more commonly used in:

• Research settings investigating metabolic syndrome, polycystic ovary syndrome (PCOS), and metabolic-associated steatotic liver disease (MASLD, formerly NAFLD)

• Specialist endocrinology or metabolic clinics where a more detailed picture of insulin dynamics is needed

• Clinical trials assessing the impact of dietary or pharmacological interventions on insulin sensitivity

For most patients attending their GP, HbA1c remains the practical, evidence-based first-line investigation for assessing glucose metabolism.

Comparing Accuracy for Detecting Insulin Resistance and Diabetes

HbA1c is the validated standard for confirming type 2 diabetes; HOMA-IR may detect early insulin resistance before HbA1c rises, but its individual-level diagnostic performance is modest and population-level findings should not be over-interpreted.

When comparing the two tests for their respective purposes, it is important to recognise that neither is universally superior — their accuracy depends on what is being measured and at what stage of metabolic disease.

For diagnosing established type 2 diabetes, HbA1c has well-validated sensitivity and specificity, and its use is endorsed by the WHO (2011), NICE, and the NHS. It performs reliably in most adult populations, though its accuracy can be affected by certain conditions (discussed in the limitations section). Where HbA1c is unreliable or inappropriate, fasting plasma glucose or an OGTT should be used.

For estimating insulin resistance before glucose levels rise, HOMA-IR may offer additional information. Research — including prospective cohort studies published in journals such as Diabetologia and The Lancet Diabetes & Endocrinology — has suggested that elevated HOMA-IR can identify individuals at higher metabolic risk before HbA1c enters the non-diabetic hyperglycaemia range. This is because insulin resistance is often accompanied by compensatory hyperinsulinaemia — the pancreas produces more insulin to maintain normal glucose levels — meaning glucose (and therefore HbA1c) may remain within the normal range even when insulin resistance is already present. However, it is important to note that HOMA-IR's individual-level diagnostic performance is modest, and these findings are primarily population-level observations.

Key comparative points:

• HbA1c is more accurate for confirming a diagnosis of type 2 diabetes and monitoring long-term glycaemic control

• HOMA-IR may provide additional information about early insulin resistance in metabolically at-risk individuals, but is a surrogate measure with limitations

• Neither test alone provides a complete metabolic picture

• HOMA-IR correlates with the gold-standard euglycaemic-hyperinsulinaemic clamp technique at a population level, but this correlation is moderate and it is not a reliable substitute at the individual level

• Where dysglycaemia is suspected and HbA1c is inappropriate, an OGTT is the recommended investigation

For clinical decision-making in the NHS, HbA1c remains the validated, guideline-supported standard. HOMA-IR adds value in specific research and specialist contexts where early insulin resistance is the primary question.

When Clinicians Use HOMA-IR Alongside HbA1c

HOMA-IR may be considered alongside HbA1c in specialist settings for conditions such as PCOS or MASLD, but NICE guidance recommends HbA1c, fasting glucose, or OGTT for routine metabolic assessment rather than HOMA-IR.

There are specific clinical scenarios in which a clinician — typically in a specialist setting — may consider requesting HOMA-IR alongside HbA1c to obtain a more detailed metabolic assessment. It is important to note that HOMA-IR is primarily a research tool and is not recommended for routine NHS clinical use by NICE or other UK guidance bodies.

Polycystic ovary syndrome (PCOS) is one context in which insulin resistance is a recognised feature of the condition's pathophysiology, contributing to hyperandrogenaemia, anovulation, and increased long-term cardiometabolic risk. However, NICE CKS guidance on PCOS recommends assessing metabolic risk using HbA1c or fasting glucose (and OGTT where indicated), rather than routine insulin or HOMA-IR measurement. HOMA-IR may be used in some research protocols or specialist assessments, but it is not a standard recommended investigation.

Metabolic-associated steatotic liver disease (MASLD, formerly NAFLD) is another area where insulin resistance is clinically relevant. NICE NG49 sets out the recommended assessment pathway for NAFLD/MASLD, which does not include routine HOMA-IR measurement. HOMA-IR may appear in research scoring systems, but clinical metabolic assessment should follow NICE guidance.

Additionally, in specialist or research settings, clinicians may consider HOMA-IR when:

• Assessing a patient with metabolic syndrome (central obesity, dyslipidaemia, hypertension, and impaired fasting glucose) as part of a detailed metabolic workup

• Monitoring the metabolic effects of medications such as antipsychotics or corticosteroids — though NICE guidance (including CG178) recommends monitoring with fasting glucose or HbA1c and lipids in this context, rather than HOMA-IR

• Conducting pre-diabetes risk stratification in individuals with a strong family history of type 2 diabetes, within a research framework

In routine NHS practice, HbA1c, fasting plasma glucose, and OGTT remain the appropriate investigations for metabolic assessment. HOMA-IR should not be requested without specialist guidance, and clinical decisions should not be based on HOMA-IR results alone.

Limitations and Factors That Affect Both Tests

HbA1c is unreliable in haemoglobinopathies, anaemia, CKD, and pregnancy; HOMA-IR lacks standardised insulin assays and a validated UK clinical cut-off, limiting its use outside research settings.

Both HOMA-IR and HbA1c have recognised limitations that clinicians must account for when interpreting results. Awareness of these factors is important for patients and healthcare professionals alike.

Limitations of HbA1c:

• Haemoglobin variants and haemolytic anaemia can falsely lower HbA1c, as red blood cell turnover is accelerated

• Iron deficiency anaemia may falsely elevate HbA1c

• Recent blood transfusion, acute blood loss, or erythropoietin therapy can alter red blood cell dynamics and render HbA1c unreliable

• Recent iron, vitamin B12, or folate replacement may affect HbA1c by altering red cell turnover

• Hypersplenism or splenectomy can affect red blood cell lifespan and therefore HbA1c

• Chronic kidney disease (CKD) — particularly advanced CKD and dialysis — and certain haemoglobinopathies (e.g., sickle cell trait, thalassaemia) can render HbA1c unreliable; in these cases, NICE CKS recommends using fasting plasma glucose or an OGTT instead

• Pregnancy alters red blood cell dynamics, making HbA1c unsuitable for diagnosing gestational diabetes; an OGTT is recommended (NICE NG3)

• Ethnicity may influence HbA1c levels independently of glycaemia, though the clinical significance of this continues to be investigated

Limitations of HOMA-IR:

• It requires fasting blood samples for both glucose and insulin, which adds complexity and patient burden

• Insulin assays are not standardised across laboratories, meaning HOMA-IR values can vary between institutions, limiting comparability

• There is no universally agreed cut-off for insulin resistance in the UK; values above 2.0–2.5 are often cited in research literature, but these thresholds are not validated for routine clinical use and are population-specific

• HOMA-IR assumes a steady-state relationship between insulin and glucose, which may not hold in individuals with significant beta-cell dysfunction

• It is a static snapshot and does not capture dynamic insulin responses to glucose loading

• The updated HOMA2 model (Oxford) addresses some limitations of the original formula but shares many of the same constraints

Neither test should be interpreted in isolation. Clinical context, patient history, and additional investigations are always necessary for accurate assessment.

Interpreting Your Results and Next Steps With Your GP

HbA1c results should be interpreted using NHS reference ranges, and HOMA-IR results require specialist explanation; clinical decisions should never be based on either test in isolation.

If you have received results for either HOMA-IR or HbA1c — or both — it is important to discuss them with your GP or specialist rather than interpreting them in isolation. Both tests provide useful information, but their significance depends on your individual clinical context, medical history, and risk factors.

For HbA1c results, the NHS uses the following reference ranges (based on WHO 2011 criteria and NHS guidance):

• Below 42 mmol/mol — normal

• 42–47 mmol/mol — non-diabetic hyperglycaemia (NDH; sometimes called prediabetes); lifestyle intervention is recommended

• 48 mmol/mol or above — diagnostic of type 2 diabetes (if confirmed on a second sample in asymptomatic individuals)

If your HbA1c falls in the non-diabetic hyperglycaemia range, your GP may refer you to the NHS Diabetes Prevention Programme (Healthier You NDPP), a structured lifestyle intervention shown to reduce the risk of progression to type 2 diabetes.

For HOMA-IR, if this has been requested — typically by a specialist — a value above approximately 2.0–2.5 may suggest insulin resistance in some research populations. However, there is no universally validated cut-off for clinical use in the NHS, and you should ask your clinician to explain what the result means in your specific situation. Clinical decisions should not be based on HOMA-IR alone.

Seek urgent medical attention on the same day if you experience:

• Rapid onset of excessive thirst, frequent urination, unexplained weight loss, or extreme fatigue — these may be symptoms of type 1 diabetes or significant hyperglycaemia and require prompt assessment

• Nausea, vomiting, or abdominal pain alongside these symptoms, which may indicate diabetic ketoacidosis (DKA) — call 999 or go to your nearest emergency department immediately

Contact your GP promptly if you experience:

• Recurrent infections or slow wound healing

• Symptoms of hypoglycaemia (shakiness, sweating, confusion) — note that hypoglycaemia is uncommon in people not taking glucose-lowering medicines or with specific endocrine conditions, and should be discussed with your GP if it occurs

Regular monitoring, a balanced diet, physical activity, and maintaining a healthy weight remain the cornerstones of preventing and managing insulin resistance and type 2 diabetes. Your GP can help you understand your results, arrange further investigations if needed, and support you in making sustainable lifestyle changes.

Frequently Asked Questions